Abstract
Uterine sarcomas are a group of rare and usually aggressive soft tissue cancers. They have a wide range of histologic appearances, from myomatous to osteous to stromal. The three major subtypes of uterine sarcomas (listed in decreasing order of incidence) are carcinosarcoma, leiomyosarcoma, and endometrial stromal sarcoma. Most patients with uterine sarcomas are middle-to older-aged women who present with abnormal uterine bleeding or pelvic mass, which may be confused with leiomyoma. Surgery—including hysterectomy and resection of disease—serves as the main treatment modality. Adjuvant therapies, including radiation, chemotherapy, and/or hormonal therapy, have limited benefit on overall survival; however, this may be due to the lack of good randomized controlled trials of sufficient size because of uterine sarcomas’ rare and aggressive nature. For patients with metastatic recurrent disease, aggressive therapy is limited by low response rates and limited duration of response. For patients with uterine sarcomas, enrollment in clinical trials is strongly encouraged.
Similar content being viewed by others
References and Recommended Reading
Brooks S, Zhan M, Cote T: Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 2004, 93:204–208.
Platz CE, Benda JA: Female genital tract cancer. Cancer 1995, 75(1 Suppl):270–294.
McMeekin D: Sarcoma of the Uterus. In: Clinical Gynecologic Oncology, end 7. Edited by DiSaia P, Creasman W. Philadelphia: Elsevier; 2007:185–199.
Silverberg S, Kurman R: Tumors of the uterine corpus and gestational trophoblastic disease. In: Atlas of Tumor Pathology. Edited by Rosai J, Sobin LH. Washington DC: Armed Forces Institute of Pathology; 1992.
Bansal N, Herzog T, Burke W, et al.: The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecol Oncol 2008, 110:43–48.
Memarzadeh S, Mundt A, Berek J: Classification, clinical manifestations, and staging of uterine sarcoma. Available at http://www.uptodate.com/patients/cotent/topic.do?topicKey=:_Md99fpsgNAsSR0. Accessed August 2008.
Ferrer F, Sabater S, Farrus B, et al.: Impact of radiotherapy on local control and survival in uterine sarcomas: a retrospective study from the Grup Oncologic Catala-Occita. Int J Radiat Oncol Biol Phys 1999, 44:47–52.
Hornback NB, Omura G, Major FJ: Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 1986, 12:2127–2130.
Knocke TH, Kucera H, Dorfler D, et al.: Results of postoperative radiotherapy in the treatment of sarcoma of the corpus uteri. Cancer 1998, 83:1972–1979.
Molpus K, Redlin-Frazier S, Reed G, et al.: Postoperative pelvic irradiation in early stage uterine mixed mullerian tumors. Eur J Gynaecol Oncol 1998, 19:541–546.
Moskovic E, MacSweeney E, Law M, Price A: Survival, patterns of spread and prognostic factors in uterine sarcoma: a study of 76 patients. Br J Radiol 1993, 66:1009–1015.
Reed NS, Mangioni C, Malmstrom H, et al.: First results of a randomized trial comparing radiotherapy versus observation postoperatively in patients with uterine sarcomas. An EORTC-GCG Study [abstract]. Int J Gynecol Cancer 2003, 13(Suppl 11):4.
Salazar O, Bonfiglio T, Patten S, et al.: Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 1978, 42:1161–1170.
Soumarova R, Horova H, Seneklova Z, et al.: Treatment of uterine sarcoma. A survey of 49 patients. Arch Gynecol Obstet 2002, 266:92–95.
Weitmann H, Knocke TH, Kucera H, Potter R: Radiation therapy in the treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 2001, 49:739–748.
Kempson R, Bari W: Uterine sarcomas: classification, diagnosis and prognosis. Hum Pathol 1970, 1:331–349.
DiSaia PJ, Pecorelli S: Gynecological sarcomas. Semin Surg Oncol 1995, 10:369–373.
Kahanpaa KV, Wahlstrom T, Grohn P, et al.: Sarcomas of the uterus: a clinicopathologic study of 119 patients. Obstet Gynecol 1986, 67:417–424.
Sherman ME, Devesa SS: Analysis of racial differences in incidence, survival and mortality for malignant tumors of the uterine corpus. Cancer 2003, 98:176–186.
Gorai I, Yanagibashi T, Taki A, et al.: Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 1997, 72:821–827.
Zelmanowicz A, Hildesheim A, Sherman ME, et al.: Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998, 69:253–257.
Sartori E, Bazzurini L, Gadducci A, et al.: Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol 1997, 67:70–75.
Greer B, Koh W, Abu-Rustum N, et al.: Uterine Neoplasms. Available at http://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf. Accessed August 2008.
Hoskins P, Le N: Preoperative tumor markers at diagnosis in women with malignant mixed müllerian tumors/carcinosarcoma of the uterus. Int J Gynecol Cancer 2008 (Epub ahead of print).
Huang GS, Chiu LG, Gebb JS, et al.: Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecol Oncol 2007, 107:513–517.
Gerszten K, Faul C, Kounelis S, et al.: The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 1998, 68:8–13.
Omura GA, Blessing JA, Major F: A randomized clinical trial of adjuvant adriamycin in uterine sarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 1985, 3:1240–1245.
Resnik E, Chambers S, Carcangiu M: A phase II study of etoposide, cisplatin and doxorubicin chemotherapy in mixed mullerian tumors (MMT) of the uterus. Gynecol Oncol 1995, 56:370–375.
Homesley HD, Filiaci V, Markman M, et al.: Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:526–531.
O’Connor D, Norris H: Mitotically active leiomyomas of the uterus. Hum Pathol 1990, 21:223–227.
Bell SW, Kempson RL, Hendrickson MR: Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994, 18:535–558.
Evans HL, Chawla SP, Simpson C, Finn KP: Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors. Cancer 1988, 62:2239–2247.
Parker W, Fu Y, Berek J: Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994, 83:414–418.
Juang CM, Yen MS, Horng HC, et al.: Potential role of preoperative serum CA125 for the differential diagnosis between uterine leiomyoma and uterine leiomyosarcoma. Eur J Gynaecol Oncol 2006, 27:370–374.
Gadducci A, Landoni F, Sartori E: Uterine leiomyosarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996, 62:25–32.
Peters W, Howard D, Andersen W, Figge D: Uterine smooth-muscle tumors of uncertain malignant potential. Obstet Gynecol 1994, 83:1015–1020.
Kapp D, Shin J, Chan J: Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer 2008, 112:820–830.
Fleming G: Gemcitabine/docetaxel—welcome to a new standard. Gynecol Oncol 2008, 109:313–315.
Hensley ML, Blessing JA, Degeest K, et al.: Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol 2008, 109:323–328.
Hensley ML, Blessing JA, Mannel R, Rose PG: Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecologic Oncology 2008, 109:329–334.
Leath C, Huh W, Hyde J, et al.: A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 2007, 105:630–634.
Evans HL: Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 1982, 50:2170–2182.
Oliva E, Clement P, Young R: Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv Anat Pathol 2000, 7:257–281.
Gadducci A, Sartori E, Landoni F, et al.: Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol Oncol 1996, 63:247–253.
Verschraegen C, Vasuratna A, Edwards C, et al.: Clinicopathologic analysis of mullerian adenosarcoma: the M.D. Anderson Cancer Center experience. Oncol Rep 1998, 5:939–944.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, J.F., Slomovitz, B.M. Uterine sarcoma 2008. Curr Oncol Rep 10, 512–518 (2008). https://doi.org/10.1007/s11912-008-0077-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11912-008-0077-9